Evidence map›Paper›PMID 30196313›Full record

ArticleWorld journal of urology2019

Alvimopan usage increasing following radical cystectomy.

Joshua D Belle, Aydin Pooli, Dimitry Oleynikov, Christopher M Deibert

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Joshua D BelleDivision of Urologic Surgery, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Joshua.belle@unmc.edu.ORCID http://orcid.org/0000-0002-5054-1652
Aydin PooliDivision of Urologic Surgery, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Dimitry OleynikovDepartment of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Christopher M DeibertDivision of Urologic Surgery, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
University of Nebraska Medical Center · USNebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC.

methodsThe Vizient database, contributed to by over 200 US academic hospitals, was evaluated from 2014 to 2016. Patients who had undergone radical cystectomy were included. Alvimopan exposure and postoperative outcomes were collected.

results7472 patients underwent cystectomy in the 3 years examined, with 3391 (45.4%) patients receiving alvimopan over this time period. The use of alvimopan increased from 35 to 59%. The receipt of alvimopan was associated with a decrease in perioperative morbidity (10.53% vs 19.23%, p = 0.027).

conclusionThis study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.

Indexed as

CystectomyAgedDrug UtilizationFemaleGastrointestinal AgentsHumansMalePiperidinesPostoperative CarePostoperative ComplicationsRetrospective StudiesalvimopanGastrointestinal AgentsPiperidinesAlvimopanBladder cancerCystectomyIleusVizient

Identifiers

PMID30196313
OpenAlexW2891152464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.